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believe that immortal time bias is the primary reason
for the discrepant findings.
Immortal time bias occurs in observational compara-
tive effectiveness studies when follow-up begins before
treatment status has been assigned. This temporal mis-
alignment leads to guaranteed or “immortal” person-
time in patients who initiate treatment (versus those who
do not) as individuals must survive to be classified as a
treatment initiator.(2,3) In Dr. Parikh’s study, patients
were included in the sorafenib group if they initiated sor-
afenib within 6 months of diagnosis, despite a median
survival in the cohort of 90 days. Thus, immortal person-
time accrued for the sorafenib group between diagnosis
and sorafenib initiation, leading to artificially protective
treatment effects. At 90 days there was already a 23.4%
absolute improvement in survival for sorafenib, at least
partially attributable to accrual of immortal time.
Parikh and colleagues addressed immortal time bias
by conducting a sensitivity analysis in which sorafenib
was included as a time-dependent exposure; this atten-
uated the treatment effect (hazard ratio, 0.87; 95%
confidence interval, 0.74-1.01). However, to
adequately evaluate the effect of time-varying sorafenib
initiation on mortality, the analysis must also address
time-varying cofounding. Changes in the health status
of HCC patients occur quickly, and such changes
unequivocally affect the likelihood of sorafenib initia-
tion and survival. Without consideration of such time-
varying confounders using appropriate statistical meth-
ods,(4) the attenuated survival benefit from sorafenib is
likely still biased.
Immortal time bias is a major concern when analyz-
ing the effectiveness of sorafenib for advanced HCC in
observational data because of the exceptionally high
rates of early death in this population. Therefore, we
recommend caution when interpreting the conclusion
of Parikh and colleagues that sorafenib improves sur-
vival and is cost-effective in Medicare beneficiaries.
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REPLY:
We appreciate the recent letter from Sanoff and col-
leagues regarding our article,(1) because they highlight
an important point regarding immortal time bias in
our analysis. Notably, there is no universally accepted
way to account for immortal time bias when analyzing
administrative data. In our immortal time bias-
adjusted analysis, we found that sorafenib use was still
associated with survival benefit; however, this crossed
the threshold for statistical significance (hazard ratio,
0.87; 95% confidence interval, 0.74-1.01). As Sanoff
and colleagues point out, time varying covariates are
also important to consider given the rapidly changing
clinical status of patients with advanced HCC. We
accounted for this with regard to sorafenib treatment;
however, we could not do so reliably for clinical status
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given the lack of granular data inherent in the SEER-
Medicare data. The approach of arbitrarily restricting
sorafenib treatment to within 60 days of diagnosis, as
used by Sanoff and colleagues, has been shown to be
imprecise, so we chose to instead perform our sensitiv-
ity analysis using treatment as the time-dependent
covariate.(2,3) Nevertheless, if we stratify our treatment
cohort as Sanoff and colleagues did, only including
patients who survived for 60 days and received sorafe-
nib within 60 days of diagnosis (treatment, n5 152;
control, n5 152) in a propensity-matched analysis, we
find that sorafenib use is still associated with a signifi-
cant survival benefit (hazard ratio, 0.77; 95% confi-
dence interval, 0.60-0.97).
There are several additional explanations for the
differences in findings between our studies. Sanoff
and colleagues defined sorafenib treatment as receipt
of sorafenib within 60 days of diagnosis, and all
other patients were placed in the control group,
including patients in whom sorafenib was initiated
after 60 days. This misclassification biases their
study results toward the null hypothesis. There was
also lack of specificity for exclusion of other adjuvant
locoregional or systemic treatments for patients on
sorafenib in their study, which were important
exclusions in our analysis. In addition, they defined
liver comorbidity solely using diagnosis codes,
whereas we also used procedural and Part D medica-
tion codes for more comprehensive capture of liver
comorbidity—an important prognostic factor in
HCC patients. Finally, although the dataset we used
in our analyses is similar, the patients included in
our analysis were diagnosed between 2007 and 2009,
whereas Sanoff and colleagues included patients
diagnosed between 2008 and 2011; therefore, some
of the differences in sorafenib-associated outcomes
may reflect the underlying differences between the
cohorts.
Given these differences in cohort selection and
methodology, we stand by our findings vis-a-vis the
findings reported by Sanoff and colleagues. We are
confident that our analysis demonstrates that sorafe-
nib treatment is associated with clinical effectiveness
in select elderly Medicare beneficiaries with
advanced HCC and is cost-effective as well.
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